Company intelligence / Profile preview
AsclepiX Therapeutics
Baltimore, Maryland, United Statesasclepix.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
AXT107 is a synthetic collagen IV-derived peptide that inhibits neovascularization by targeting VEGFR2 and activating Tie2 pathways. It forms an intravitreal self-forming gel depot allowing potentially yearly dosing versus frequent injections required by current anti-VEGF therapies. Animal models show superiority over Eylea with longer durability. The Phase1/2a CONGO trial has dosed patients with diabetic macular edema demonstrating safety and bioactivity.
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Peptide therapeuticsComputational biology-driven peptide discovery platformIntravitreal self-forming gel depot delivery system
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on AsclepiX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AsclepiX Therapeutics.